Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$38.93 USD
-0.41 (-1.04%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.90 -0.03 (-0.08%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.93 USD
-0.41 (-1.04%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.90 -0.03 (-0.08%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Zacks News
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -20.59% and -1.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 36.67% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 39.13% and 1.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Q2 Earnings Miss Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -4.17% and 4.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMRX vs. COLL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMRX vs. COLL: Which Stock Is the Better Value Option?
AMRX vs. COLL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMRX vs. COLL: Which Stock Is the Better Value Option?
AMRX or COLL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMRX vs. COLL: Which Stock Is the Better Value Option?
AMRX or COLL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMRX vs. COLL: Which Stock Is the Better Value Option?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Growth Stocks to Buy for April 6th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 6th
Top Ranked Growth Stocks to Buy for April 1st
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 1st
COLL or NBIX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COLL vs. NBIX: Which Stock Is the Better Value Option?
Top Ranked Growth Stocks to Buy for March 20th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 20th
COLL or NBIX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COLL vs. NBIX: Which Stock Is the Better Value Option?
Why Collegium (COLL) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Collegium (COLL).
Assertio (ASRT) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.
Prospects Appear Bright for Small Drug Industry in 2020
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity keep small drugmakers afloat in a competitive market.
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Collegium Pharmaceutical (COLL) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -12.50% and -1.76%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 152.63% and -1.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?